Understanding the current status helps navigate access appropriately
SSRIs increase serotonin broadly, and the downstream effect on 5-HT2C receptors specifically suppresses sexual desire and delays or prevents orgasm
TRIUMPH-1, the pivotal obesity trial, reported on May 21, 2026 , and TRIUMPH-2 (obesity in type 2 diabetes) and TRIUMPH-3 (obesity with established cardiovascular disease) both reported on July 23, 2026 so the core evidence package for this filing is in hand
Ongoing research investigates whether GLP-1-based therapies may offer benefits for neurodegenerative conditions, though such applications remain investigational and are not FDA-approved
Li Z, Han Z, Sun R, Xuan X, Huang C
Safer, Evidence-Based Alternatives Available Through the NHS NICE-recommended semaglutide (Wegovy) and MHRA-authorised tirzepatide (Mounjaro) are regulated, evidence-based options for weight management available through NHS specialist services